TearLab reported a net loss of $0.9 million, or $0.09 per share, in the first quarter of 2018 compared with a net loss of $4.4 million, or $0.82 per share, in the same time period of 2017.
Revenues for the quarter decreased 3.8% from 2017’s total of $6.7 million to $6.4 million this year, according to a press release.
Research and development costs decreased from $1.5 million to $1 million for the quarter, while general and administrative costs went down from $2.2 million to $2 million.
The company had $7.4 (Read more...)
Author: Healio ophthalmology
TearLab posts quarterly net loss
TearLab reported a net loss of $0.9 million, or $0.09 per share, in the first quarter of 2018 compared with a net loss of $4.4 million, or $0.82 per share, in the same time period of 2017.
Revenues for the quarter decreased 3.8% from 2017’s total of $6.7 million to $6.4 million this year, according to a press release.
Research and development costs decreased from $1.5 million to $1 million for the quarter, while general and administrative costs went down from $2.2 million to $2 million.
The company had $7.4 (Read more...)
VIDEO: Panel recommends NSAIDs in cataract surgery in CME
KIAWAH ISLAND, S.C. — At the Kiawah Eye meeting here, Preeya Gupta, MD, discusses whether or not to use NSAIDs in cataract surgery for patients with cystoid macular edema.
VIDEO: Panel recommends NSAIDs in cataract surgery in CME
KIAWAH ISLAND, S.C. — At the Kiawah Eye meeting here, Preeya Gupta, MD, discusses whether or not to use NSAIDs in cataract surgery for patients with cystoid macular edema.
VIDEO: Surgeon shares pearls on when to use FLACS
KIAWAH ISLAND, S.C. — At the Kiawah Eye meeting here, Elizabeth Yeu, MD, shares pearls on cases in which femtosecond laser-assisted cataract surgery is necessary for beyond refractive purposes.
VIDEO: Surgeon shares pearls on when to use FLACS
KIAWAH ISLAND, S.C. — At the Kiawah Eye meeting here, Elizabeth Yeu, MD, shares pearls on cases in which femtosecond laser-assisted cataract surgery is necessary for beyond refractive purposes.
June is Cataract Awareness Month
Prevent Blindness has named June Cataract Awareness Month, using the designation to educate the public about risk factors, symptoms and treatment options.
More than 25 million Americans have cataract, with that number expected to grow to 38.5 million by 2032 and 45.6 million by 2050, according to the organization.
Risk factors include aging, intense heat or long-term UV exposure, inflammation, certain diseases such as diabetes, hereditary influences, eye injuries and smoking.
Healio.com/OSN presents the top five cataract-related articles from the first half of 2018:
FDA approves Dexycu to
June is Cataract Awareness Month
Prevent Blindness has named June Cataract Awareness Month, using the designation to educate the public about risk factors, symptoms and treatment options.
More than 25 million Americans have cataract, with that number expected to grow to 38.5 million by 2032 and 45.6 million by 2050, according to the organization.
Risk factors include aging, intense heat or long-term UV exposure, inflammation, certain diseases such as diabetes, hereditary influences, eye injuries and smoking.
Healio.com/OSN presents the top five cataract-related articles from the first half of 2018:
FDA approves Dexycu to
VIDEO: OCT before cataract surgery should be standard of care
KIAWAH ISLAND, S.C. — At the Kiawah Eye meeting here, Steve Charles, MD, lays out the reasons why he believes all patients undergoing cataract surgery should receive a retina evaluation with OCT before surgery to rule out possible underlying retinal pathology that cannot be seen by other methods.
VIDEO: OCT before cataract surgery should be standard of care
KIAWAH ISLAND, S.C. — At the Kiawah Eye meeting here, Steve Charles, MD, lays out the reasons why he believes all patients undergoing cataract surgery should receive a retina evaluation with OCT before surgery to rule out possible underlying retinal pathology that cannot be seen by other methods.
New ARVO leadership assumes roles
The new president of the Association for Research in Vision and Ophthalmology, Steven J. Fliesler, PhD, FARVO, has begun his 2018-2019 term, succeeding Claude F. Burgoyne, MD, FARVO, according to a press release.Fliesler is the Meyer H. Riwchun Endowed…
New ARVO leadership assumes roles
The new president of the Association for Research in Vision and Ophthalmology, Steven J. Fliesler, PhD, FARVO, has begun his 2018-2019 term, succeeding Claude F. Burgoyne, MD, FARVO, according to a press release.Fliesler is the Meyer H. Riwchun Endowed…
New ARVO leadership assumes roles
The new president of the Association for Research in Vision and Ophthalmology, Steven J. Fliesler, PhD, FARVO, has begun his 2018-2019 term, succeeding Claude F. Burgoyne, MD, FARVO, according to a press release.Fliesler is the Meyer H. Riwchun Endowed…
Kala posts quarterly loss
Kala Pharmaceuticals reported a net loss of $11.3 million in the first quarter of 2018 compared with a net loss of $9.8 million in the same time period of 2017, according to a company press release.
General and administrative expenses increased from $1.5 million in 2017’s first quarter to $5.5 million this year, while research and development expenses decreased from $8 million to $5.7 million.
The company had cash of $100.5 million as of March 31.
Kala posts quarterly loss
Kala Pharmaceuticals reported a net loss of $11.3 million in the first quarter of 2018 compared with a net loss of $9.8 million in the same time period of 2017, according to a company press release.
General and administrative expenses increased from $1.5 million in 2017’s first quarter to $5.5 million this year, while research and development expenses decreased from $8 million to $5.7 million.
The company had cash of $100.5 million as of March 31.
APAO welcomes new member societies
Last month we featured the Asia Pacific Tele-Ophthalmology Society in the APAO Edition of Ocular Surgery News. This month we conclude the introduction to our new members by featuring the Asian Neuro-Ophthalmology Society, an associate member of the Asia-Pacific Academy of Ophthalmology.
Founded in 2002, the Asian Neuro-Ophthalmology Society (ASNOS) holds scientific meetings every 2 years with a unique clinicopathologic case presentation conference in the style of the Frank B. Walsh Society meeting, known as “Walsh in Asia,” to promote and expedite the development of
APAO welcomes new member societies
Last month we featured the Asia Pacific Tele-Ophthalmology Society in the APAO Edition of Ocular Surgery News. This month we conclude the introduction to our new members by featuring the Asian Neuro-Ophthalmology Society, an associate member of the Asia-Pacific Academy of Ophthalmology.
Founded in 2002, the Asian Neuro-Ophthalmology Society (ASNOS) holds scientific meetings every 2 years with a unique clinicopathologic case presentation conference in the style of the Frank B. Walsh Society meeting, known as “Walsh in Asia,” to promote and expedite the development of
Iridex posts first quarter net loss
Iridex reported a net loss of $3.6 million in the first quarter of 2018 compared with a net loss of $1.9 million in 2017’s first quarter.
Operating expenses for the quarter rose from $6.3 million in 2017 to $7.5 million this year, which Iridex attributed to investments supporting its commercial infrastructure, including sales and marketing expense increases, according to a press release.
Revenue was down from $10.5 million in the first quarter of 2017 to $9.5 million. The decrease was attributed to lower retina product revenues due to the voluntary (Read more...)
Iridex posts first quarter net loss
Iridex reported a net loss of $3.6 million in the first quarter of 2018 compared with a net loss of $1.9 million in 2017’s first quarter.
Operating expenses for the quarter rose from $6.3 million in 2017 to $7.5 million this year, which Iridex attributed to investments supporting its commercial infrastructure, including sales and marketing expense increases, according to a press release.
Revenue was down from $10.5 million in the first quarter of 2017 to $9.5 million. The decrease was attributed to lower retina product revenues due to the voluntary (Read more...)
FDA issues draft guidance to promote competition, access to drugs
The FDA released several draft guidances today that it said it hopes will assist generic drug makers get their products through the development and approval process while keeping the agency’s Risk Evaluation and Mitigation Strategy, or REMS, safety controls in place.
“Bringing together multiple products under one REMS program can have real benefits for the health care system, including for providers. But, the generic drug maker has to negotiate with the brand firm to enter into a shared REMS programs before the generic drug can be approved. We know that (Read more...)